Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00747604 · ClinicalTrials.gov registry record
IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex
A clinical trial, sponsored by Ipsen.
- Terminated
- Registry status
- 1,378
- Enrollment target
NCT00747604 is a clinical trial that was terminated before completion, run by Ipsen. The registered enrollment target is 1,378 participants.
The verdict
NCT00747604 was terminated before completion, sponsored by Ipsen.
- TERMINATED
- Registry status
- 1,378 participants
- Enrollment target
Study Summary
This project is a retrospective (beginning January 2006) and prospective patient registry program sponsored by Ipsen (formerly Tercica, Inc.). In collaboration with participating health care practitioners, the patient registry program is an observational study monitoring the long-term safety of patients treated with Increlex® (mecasermin \[rDNA origin\] injection). The IGFD (Increlex® Growth Forum Database) Registry is intended primarily to monitor the safety and efficacy of Increlex replacement therapy in children with growth failure.
Interventions
- BIOLOGICAL mecasermin [rDNA origin] injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,378 participants |
| Start Date | 2006-06 |
| Est. Completion | 2014-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00747604
The ClinicalTrials.gov registry entry for NCT00747604 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1,378 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mecasermin [rDNA origin] injection is the first listed.
NCT00747604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00747604 about?
NCT00747604 is a clinical study titled "IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex". This project is a retrospective (beginning January 2006) and prospective patient registry program sponsored by Ipsen (formerly Tercica, Inc.). In collaboration with participating health care practitioners, the patient registry program is an observational study monitoring the long-term safety of pati...
What is the current status of trial NCT00747604?
This trial is currently terminated. The enrollment target is 1,378 participants. The study started on 2006-06. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00747604?
The interventions under investigation include: mecasermin [rDNA origin] injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT00747604?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.